NSABP


Also found in: Acronyms.

NSABP

National Surgical Adjuvant Breast Project Oncology A series of ongoing multicenter clinical trials evaluating the effects of various therapies, including RT, surgery and chemotherapy–eg, tamoxifen and 5-FU, in treating advanced breast or colorectal CAs
References in periodicals archive ?
Although previous studies such as NSABP B-17 showed that patients with DCIS breast cancer benefitted from radiation, the issue in DCIS has been the absence of a reliable way to specifically identify those patients that are at such low risk of recurrence that they can forego radiation," said Norman Wolmark, M.
This analysis of 1,674 patients from previous NSABP B-14 and B-20 randomized clinical trials (895 tamoxifen-treated patients, 355 placebo-treated patients and 424 chemotherapy plus tamoxifen-treated patients) demonstrated a clear association between the Recurrence Score results as identified by Oncotype DX and risk for loco-regional recurrence (LRR).
In NSABP B-17, 818 women with DCIS underwent lesion excision to a negative margin and were then randomly assigned to radiotherapy or no treatment.
He is the principal research investigator for the National Cancer Institute approved National Surgical Adjuvant Breast Project (NSABP) and NSABP Breast Cancer Prevention Trial and is co-investigator for the Southwest Oncology Group Project #15858.
The NSABP conducted three development studies and Cleveland Clinic conducted one development study, which was funded by Genomic Health, analyzing 761 genes from 1,851 patients with stage II colon cancer.
And to dispel criticism that NSABP was too lax with problem institutions, Herberman said that the project would alert the National Cancer Institute (NCI) within 24 hours of finding data problems.
He returned to the NSABP as the Director of the Division of Pathology in 1996.
Among whites--the predominant patient population in NSABP B-14-the prevalence of one major inactivating polymorphism is about 10%, whereas recent studies indicate that in some parts of Asia it's 40%-50%.
Raloxifene did as well as tamoxifen, although in a smaller overall study group, with a lower endometrial cancer risk, in the subsequent NSABP P-2 investigation, the Study of Tamoxifen and Raloxifene (STAR) trial (JAMA 2006;295:2727-41).
NSABP first came under fire after reports that a Montreal physician had falsified data underlying a study reported in 1985 that compared lumpectomy to mastectomy for the treatment of breast cancer (see p.